Genetic Signatures (GSS) H2 2026 earnings summary

Executive summary

• FY 2026 revenue was $14.8 million, down 7% year-over-year due to increased competition and a delayed or muted respiratory/flu season.

• Net loss reduced by 30% to $14.0 million, reflecting improved operational performance, cost control, and restructuring.

• Cash outflow decreased to $7.8 million from $12.3 million, with a year-end cash balance of $22.1 million and no debt.

• Organisational restructuring completed, expected to deliver up to $5 million in annual cost savings from FY2027.

• Secured long-term supply agreements, including a 10-year contract with Hvidovre Hospital in Denmark and new agreements in Australia.

Financial highlights

• Net operating cash outflow dropped 37% year-over-year to $7.8 million, including $0.8 million in redundancy payments.

• Cash and term deposits at June 30, 2026 were $22.1 million, with no debt.

• Employee expenses reduced by 16% due to restructuring.

• Gross profit fell to $6.3 million from $8.8 million in FY25, with gross margin on materials declining to 43% from 55% due to higher input costs and inventory write-downs.

• Inventory reduced to $6.2 million from $9.1 million year-over-year.

Outlook and guidance

• Focus on stabilizing, optimizing, and scaling the business over three strategic horizons, with new product launches anticipated from early next year.

• Reliable annual revenues expected from long-term supply agreements and new customer relationships.

• APAC and EMEA regions targeted for future growth, with APAC expected to provide substantial opportunities in the medium term.

• Profitability remains a key focus, but timing is uncertain due to market variables.

• US market access strategy being reset, including potential launch as laboratory developed tests.